|
Published by: Datamonitor
Published: Jan. 6, 2003 - 102 Pages
Table of Contents
CHAPTER 1 EXECUTIVE SUMMARY
CHAPTER 2 OVERVIEW
Introduction
Disorder definition
ADHD etiology
Dopamine receptor genes
Dopamine transporters
Awareness of ADHD
US
Japan
France
Germany
Italy
Spain
UK
Country specific attitude to ADHD
US
Japan
France
Germany
Italy
Spain
UK
CHAPTER 3 EPIDEMIOLOGY
Introduction
Prevalence
Gender prevalence
Prevalence by age
Future prevalence
Comorbidities
CHAPTER 4 DIAGNOSIS
Introduction
Diagnosis of ADHD
ADHD misdiagnosis
Diagnostic guidelines
Diagnosis tools
Attention Deficit Disorders Symptom Questionnaire
The Conners rating scales
SNAP-IV rating scale
TOVA assessment for ADHD diagnosis and for medication titration
Quantitative electroencephalographic (QEEG) Assessment
Country specific diagnosis methods
Historical diagnosis
Initiatives to improve diagnosis
CHAPTER 5 TREATMENT
Introduction
Overview
Behavioral therapy
Parent training
Teacher training
Pharmacotherapy treatment
Use of pharmacotherapy
Marketed drugs
Methylphenidate based drugs
Amphetamine based drugs
Others
First-line treatment of ADHD
US physicians
European physicians
Japanese physicians
CHAPTER 6 PHYSICIAN NEEDS
Introduction
Endpoints when treating patients
Endpoints used by physicians
Clinical trial endpoints
Drug delivery
Once daily formulations
More delivery choice
Non-stimulants
Abuse of ADHD stimulants
Use of non-stimulants
Physician unmet needs
Reduced side effects
Longer action drugs
Novel mechanisms
Improved delivery
Restricted use
CHAPTER 7 STRATTERA—CASE STUDY
Introduction
Clinical data and market positioning
Efficacy
Side effect profile
Non-scheduled
Manufacturing issues at Lilly
Jpotential of the Japanese market
Strattera SWOT summary
Datamonitor Recommendations
CHAPTER 8 THE FUTURE DECODED
Introduction
Key pipeline products
GW
MethyPatch(R)
SPD and SPD
Global forecast to
CHAPTER 9 APPENDIX A
Bibliography
Books
Websites
Opinion Leaders
CHAPTER 10 APPENDIX B: ABOUT DATAMONITOR
About Datamonitor
About Datamonitor Healthcare
Datamonitor Healthcare’s therapy area capabilities
About CNS analysis team
Datamonitor Healthcare’s Consulting expertise
Key therapy team members
Disclaimer
DATASETS
Figure 1: Key events of the ADHD market, 2002-10
Figure 2: Physician perceived prevalence of ADHD, 2002
Figure 3: Patient potential versus diagnosed patient potential, 2002
Figure 4: Patients population (000s) of ADHD in the seven major markets, split by gender, 2002
Figure 5: Gender split of treated ADHD patients
Figure 6: Distribution of ADHD patients by age across the seven major markets, 2002
Figure 7: Future prevalence of ADHD, 2002
Figure 8: Physician perception of comorbidities with ADHD across the seven major markets, 2002
Figure 9: Percentage of ADHD patients diagnosed, 2002
Figure 10: Diagnostic methods in the seven major markets, 2002
Figure 11: Treatment algorithm for children with ADHD
Figure 12: Proportion of ADHD patients pharmacologically treated by age, 2002
Figure 13: Proportion of ADHD patients treated pharmacologically, split by gender (all ages), 2002
Figure 14: Pharmacokinetics of Ritalin and Ritalin LA
Figure 15: Release rate of Concerta and resulting serum levels
Figure 16: Metadate CD versus immediate release methylphenidate (MPH)
Figure 17: Level of need for new ADHD drug delivery mechanisms
Figure 18: Unmet needs in the ADHD market, 2002
Figure 19: Patient flow diagram (ATM = atomoxetine)
Figure 20: Change from baseline in ADHD-RS scale score (A) and CGI-S (B)
Figure 21: SWOT profile of Strattera, 2002
Figure 22: Datamonitor’s Healthcare Consultancy
Figure 23: Therapeutic Consulting capabilities
Table 1: ADHD key market metrics, 2002-10
Table 2: Forecast of key ADHD drugs, 2002-10 ($m)
Table 3: Sales data of key methylphenidate products, 2002
Table 4: Parameters of Ritalin and Ritalin SR
Table 5: Sales data of key amphetamine based products, 2002
Table 6: Efficacy on the CGIS-T of Adderall XR in the morning and afternoon at various doses
Table 7: Use of endpoints at various ages
Table 8: Forecasts of key ADHD drugs, 2002-10 ($m)
Table 9: Sales data of key methylphenidate products, 2002
Table 10: Sales data of key amphetamine based products, 2002
AbstractIntroduction: Currently, the ADHD market is dominated by methylphenidate (Ritalin and Concerta) and amphetamine (Adderall) based stimulants. However, in November 2002, Eli Lilly’s Strattera (atomoxetine) received FDA approval. Strattera will be the first drug indicated for ADHD that is not a Schedule II Controlled Substance, and this provides Strattera with a plethora of competitive advantages that will see the drug rival Concerta and Adderall. Scope: * Key data and detailed analysis of the 7 leading pharmaceutical markets: the US, Japan, Germany, France, Italy, Spain, and the UK * Focus on Eli Lilly’s Strattera, including clinical data assessment and market positioning strategy * Forecast revenues of the branded market and specific products to 2010 * In-depth analysis of, and strategies to increase, awareness of ADHD in the seven major markets. Report Highlights: There is a low diagnosis rate of females with ADHD compared to males due to the former having more internalized symptoms. However, Datamonitor has found that females are also less likely to be treated with pharmacotherapy and Datamonitor believes that this is due to clinical trial data focusing on hyperactivity rather than inattentive symptoms.Eli Lilly’s Strattera will receive a fast uptake because it the first non-Schedule II drug approved for ADHD. This means that samples can be provided to physicians, prescriptions can be re-filed, and the drug does not have be securely stored. Reasons to Purchase: * Understand the unmet needs of the ADHD market to optimize growth strategies * Enhance your understanding of how Eli Lilly’s Strattera will impact the market, and in which areas * Understand the key mechanisms to drive awareness and diagnosis rates of ADHD, and countries where this is most required * Increase your competitive intelligence through assessments of product performance to 2010
Get Full Details About This Report >>
|
